Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cyclacel
Biotech
Cyclacel sheds clinical asset in effort to stop cash spiral
The company is now focusing on its sole remaining clinical asset, a PLK 1 inhibitor designed to treat advanced cancers and hematological malignancies.
Darren Incorvaia
Apr 2, 2025 6:01pm
Amylyx preps for GLP-1 launch with new CCO—Chutes & Ladders
Jan 10, 2025 8:30am
Investor pumps $3M into Cyclacel in return for CEO role
Jan 3, 2025 10:50am
Cash-strapped Cyclacel cuts costs while searching for salvation
Dec 6, 2024 9:11am
Ex-Eisai leader to be new NextPoint CEO—Chutes & Ladders
Feb 2, 2024 9:30am
Cyclacel passes phase 3 leukemia drug rights back to Daiichi
Nov 10, 2022 10:05am
